Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Cardiology | Internal Medicine | Nursing | Journal

Back to Journal Articles

Long-Term Safety Shown for Biodegradable Stent

Last Updated: April 17, 2012.

 

Data shows long-term safety of the Igaki-Tamai stent in cardiac patients over more than 10 years

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Long-term follow-up indicates that the fully biodegradable Igaki-Tamai stent is safe for coronary artery use in humans, according to a study published online April 16 in Circulation.

TUESDAY, April 17 (HealthDay News) -- Long-term follow-up indicates that the fully biodegradable Igaki-Tamai stent is safe for coronary artery use in humans, according to a study published online April 16 in Circulation.

Soji Nishioa, M.D., of the Shiga Medical Center for Adults in Japan, and colleagues followed 50 patients with 63 lesions that were treated with 84 Igaki-Tamai stents, for more than 10 years. Major adverse cardiac events (MACE; including all-cause death, nonfatal myocardial infarction [MI] and target lesion revascularization/target vessel revascularization [TLR/TVR]) and rates of scaffold thrombosis were analyzed. Patients were assessed with angiography and intravascular ultrasound (IVUS).

During the clinical follow-up, the researchers found that two patients were lost to follow-up and there was one cardiac death, six non-cardiac deaths, and four MIs. At 10 years, survival rates free of all-cause death, cardiac death, and MACE were 87, 98, and 50 percent, respectively. The cumulative rates of TLR and TVR were both 16 percent at one year; 18 and 22 percent, respectively, at five years; and 28 and 38 percent, respectively, at 10 years. There were two definite scaffold thromboses recorded: one subacute and one very late, which was related to a sirolimus-eluting stent implanted for a lesion proximal to an Igaki-Tamai stent. Evidence from IVUS analysis showed that, within three years, the stent struts mostly disappeared.

"Acceptable MACE and scaffold thrombosis rates without stent recoil and vessel remodeling suggested the long-term safety of the Igaki-Tamai stent," the authors write.

One author invented and developed the Igaki-Tamai stent and is employed by the Kyoto Medical Planning Co. Ltd., which commercialized the technology.

Abstract
Full Text

Copyright © 2012 HealthDay. All rights reserved.


Previous: 2001 to 2006 Saw Increase in Mohs Surgery for Skin Cancer Next: Preexposure Chemoprophylaxis Cuts HIV Infection at a Cost

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.